Skip to main content
[Preprint]. 2021 May 4:2021.05.03.442357. [Version 1] doi: 10.1101/2021.05.03.442357

Figure 3. CMA3p20 strain maintains human replication capacity and antigenicity.

Figure 3.

a-b) Primary human airway cultures were infected with SARS-CoV-2 WT (black) or CMA3p20 (blue) at an MOI of 0.01 and evaluated for a) viral titer and b) viral RNA. c) Sera collected from female Balb/c mice 28 days post infection with 106 PFU of SARS-CoV-2 CMA3p20 were evaluated for capacity to neutralize WT SARS-CoV-2 via PRNT50 assay. d) PRNT50 values from COVID19 patient sera plotted against WT virus (y-axis) versus CMA3p20 virus (x-axis). e-f) Ten-week-old female Balb/c mice were treated intraperitoneally with 100ul of human COVID19 sera or control (PBS) one day prior to infection. Mice were subsequently challenged with 105 PFU of SARS-CoV-2 CMA3p20 and evaluated for e) weight loss and f) viral titer in the lung.